Why tumour type is the first question, not a formality
Immunotherapy is not one treatment. It is a group of approaches that help the immune system recognise or attack cancer cells, and the National Cancer Institute notes that whether it is appropriate depends on the cancer and the individual. That single sentence explains why a hospital cannot answer "can I have immunotherapy in China?" from a diagnosis label alone. The tumour type tells the clinical team which immune pathways are plausibly involved, which approved or investigational options exist for that disease, and which questions still need answers.
This matters for overseas planning because immunotherapy is often discussed as if it were a single switch. In practice, a lung cancer, a melanoma, a bladder cancer and a lymphoma are different diseases with different immune biology and different evidence. A specialist reviewing your file will want to know the exact diagnosis, the stage, the pathology report and any molecular or biomarker results before commenting on suitability. Without those, any reply is generic.
So the practical starting point is not a treatment name. It is a clear statement of what you have, what has already been tried, and what your current treating team is recommending. That package is what makes a China enquiry useful rather than a request for a brochure.
Biomarkers: the results that decide whether a conversation is possible
For several cancers, immunotherapy decisions depend on biomarker results rather than the tumour type alone. These may include tests such as PD-L1 expression, mismatch repair status or other molecular findings, depending on the disease. The NCI source does not list which biomarker applies to which cancer, and no article should pretend it does. What matters for your planning is whether those tests have been done, whether the reports are available in a form a Chinese specialist can read, and whether the original tissue block or slides can be requested if re-testing is needed.
A missing biomarker result is not a reason to give up on an enquiry. It is a reason to ask a specific question: for my diagnosis and stage, which biomarker results would the treating team need before it can say whether immunotherapy is appropriate? That question is answerable, and it tells you what to collect next.
Be careful with reports that only give a conclusion without the method, the antibody clone or the reference range. A receiving clinician may need the full laboratory report, not a summary line. Ask your current hospital for the complete document set rather than a screenshot.
Previous treatment changes what can be offered next
Immunotherapy is often considered after surgery, radiotherapy, chemotherapy or targeted therapy, or alongside them. The sequence matters. A specialist assessing you in China needs to know which treatments you have already received, when, at what dose schedule, and how the cancer responded. They also need to know about any immune-related side effects you experienced, because those can affect whether a further immune-based approach is considered.
This is where a short, dated treatment timeline is more useful than a thick folder. List each line of treatment in order, with start and stop dates, the reason it stopped, and the response recorded by your treating team. Add any hospital admissions or significant adverse events. If your current team has already discussed immunotherapy and decided against it, say so and explain why. That information prevents a Chinese specialist from repeating a step you have already taken.
Do not stop or delay your current treatment while preparing an overseas enquiry. Any change to an active plan belongs with the clinicians treating you now.
What a China assessment can and cannot tell you
A records-based review can clarify whether your diagnosis and history make immunotherapy worth discussing, which additional tests or documents are missing, and which type of specialist or hospital department would be relevant. It cannot confirm that a particular drug is available to you, that a hospital will accept your case, or that you are eligible for a clinical trial. Those are decisions for the treating hospital and its clinicians, based on their own assessment and their own rules.
It also cannot tell you how your cancer will respond. Immunotherapy does not work for every cancer or every patient, and the NCI source is explicit that appropriateness depends on the cancer and individual assessment. Any estimate you are given should come with its uncertainty, and you are entitled to ask your clinician about evidence-based risks and expected outcomes for your situation.
The honest framing is this: tumour type, biomarkers and prior treatment determine whether a meaningful conversation is possible. They do not determine the outcome of that conversation.
Questions to ask before you commit to travel
Once your records are in front of a specialist, the useful questions are specific. Ask whether immunotherapy is appropriate for your exact diagnosis and stage, and on what evidence that view is based. Ask which biomarker or pathology results were used, and whether any are missing or need re-testing. Ask what alternatives exist if immunotherapy is not suitable, including chemotherapy, targeted therapy, radiotherapy or a clinical trial pathway.
Ask how your care would be monitored if you started treatment in China, and how that monitoring would continue after you return home. Ask who would be responsible for follow-up, what records would be sent back to your local team, and what would happen if you developed a side effect after leaving. These are practical questions, and a hospital that cannot answer them clearly is telling you something important.
Finally, ask for the scope of any written estimate in advance. Ask what the quoted figure includes, what it excludes, and what remains undecided. Do not assume a particular charge is separate or included; ask the named provider how its own estimate works.
- Is immunotherapy appropriate for my exact diagnosis and stage, and based on what evidence?
- Which biomarker or pathology results were used, and are any missing?
- What alternatives exist if immunotherapy is not suitable for me?
- How would monitoring work during treatment, and how would it continue at home?
- What does the written estimate include, exclude, and leave undecided?
Preparing your records and taking the next step
A useful first summary is short. Include your diagnosis in plain terms, the date it was confirmed, the stage if known, the biomarker results you have, a dated list of previous treatments with responses, your current medication and any significant side effects, and your main question. You do not need to send a complete medical archive at the first contact, and you should not send passport numbers or payment details.
After that first contact, the team can explain how to share the fuller records, such as pathology reports, imaging reports and discharge summaries. If you have tissue blocks or slides, ask your current hospital whether they can be released and in what form; do not assume this is automatic. If you are unsure which documents matter, ask before paying for translations or couriers.
An initial enquiry is free and does not commit you to anything. It is a way to find out whether your case is one where a China-based review would add useful information, and what the next practical step would be. A proxy consultation is optional and is not a prerequisite for every appointment or treatment. The hospital, not the coordination team, decides suitability and acceptance.
If your symptoms are worsening or you need urgent care, contact your local clinicians first. An overseas enquiry can wait; an acute problem should not.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.